Status:

RECRUITING

Cochlear Implantation in Children With Asymmetric Hearing Loss or Single-Sided Deafness Clinical Trial

Lead Sponsor:

Washington University School of Medicine

Collaborating Sponsors:

St. Louis Children's Hospital

University of Southern California

Conditions:

Asymmetric Hearing Loss

Single-sided Deafness

Eligibility:

All Genders

4-14 years

Phase:

NA

Brief Summary

This is a two-phase study that compares performance growth pre-implant with current hearing aid (HA) technology versus post-implant with a cochlear implant (CI) in children with either asymmetric hear...

Detailed Description

The study is conducted as a multicenter, prospective, two-phase clinical trial, evaluating the efficacy and safety of cochlear implantation in children with asymmetric hearing loss (AHL) or single-sid...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • At least 4 ys of age and up to 14 yrs, 11 mos of age and able to complete all investigational procedures.
  • Parents and child fluent in English. Parents desire bilateral hearing for their child, are willing to comply with study requirements, including the pre-implant HA phase, and are able to provide informed consent.
  • Poor ear (AHL/SSD): PTA at .5, 1, 2 kHz \> 70 dB HL; Aided CNC word recognition score at 60 dB SPL \< 40%; SPHL duration ≥ 6 mos and ≤ 10 yrs at time of CI surgery; If \> 5 yrs of age, evidence of non-congenital SPHL onset (e.g., passed newborn hearing screening); If ≤ 5 yrs of age, no restrictions on SPHL onset.
  • Better ear
  • AHL: PTA at .5, 1, 2, 4 kHz \> 25 and ≤ 60 dB HL; Aided CNC word score at 60 dB SPL ≥ 55%; Currently using a HA; Stable hearing for the past 6-mo period. "Stable" is defined as thresholds that have not declined by more than 20 dB at three or more octave-interval audiometric frequencies.
  • SSD: PTA at .5, 1, 2, 4 kHz ≤ 25 dB HL; CNC word score at 60 dB SPL ≥ 70%; Stable hearing for the past 6-mo period.
  • Both ears of NH participants: PTA at .5, 1, 2, 4 kHz ≤ 25 dB HL.
  • To continue with cochlear implantation and into the CI phase of the study: Indication, via imaging, of a normal cochlear nerve and of cochlear anatomy in the ear to be implanted that allows full insertion of the electrode array. Imaging modality is at the discretion of the surgeon. In addition, better ear hearing must be stable throughout the HA phase.
  • Exclusion Criteria for AHL/SSD Participants:
  • Medical condition that contraindicates surgery; Actively using an implantable device in the ear to be implanted; Inability to complete study procedures; Unrealistic expectations related to the benefits and limitations of implantation; Unwillingness or inability to comply with all investigational requirements.
  • Exclusions for cochlear implantation and the CI phase of the study: Cochlear malformation or obstruction that would preclude full insertion of the electrode array in the ear to be implanted; Abnormal cochlear nerve in the ear to be implanted; Hearing loss of neural or central origin.

Exclusion

    Key Trial Info

    Start Date :

    September 20 2021

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    August 1 2026

    Estimated Enrollment :

    80 Patients enrolled

    Trial Details

    Trial ID

    NCT04793412

    Start Date

    September 20 2021

    End Date

    August 1 2026

    Last Update

    April 2 2025

    Active Locations (5)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (5 locations)

    1

    Keck School of Medicine of the University of Southern California

    Los Angeles, California, United States, 90033

    2

    Fairview Health Services

    Minneapolis, Minnesota, United States, 55454

    3

    Washington University School of Medicine/St Louis Children's Hospital

    St Louis, Missouri, United States, 63110

    4

    Hearts for Hearing

    Oklahoma City, Oklahoma, United States, 73120